Mas-related G protein–coupled receptor X2 and its activators in dermatologic allergies - 04/02/21
Abstract |
The Mas-related G protein–coupled receptor X2 (MRGPRX2) is a multiligand receptor responding to various exogenous and endogenous stimuli. Being highly expressed on skin mast cells, MRGPRX2 triggers their degranulation and release of proinflammatory mediators, and it promotes multicellular signaling cascades, such as itch induction and transmission in sensory neurons. The expression of MRGPRX2 by skin mast cells and the levels of the MRGPRX2 agonists (eg, substance P, major basic protein, eosinophil peroxidase) are upregulated in the serum and/or skin of patients with inflammatory and pruritic skin diseases, such as chronic spontaneous urticaria or atopic dermatitis. Therefore, MRGPRX2 and its agonists might be potential biomarkers for the progression of cutaneous inflammatory diseases and the response to treatment. In addition, they may represent promising targets for prevention and treatment of signs and symptoms in patients with skin diseases or drug reactions. To assess this possibility, this review explores the role and relevance of MRGPRX2 and its activators in cutaneous inflammatory disorders and chronic pruritus.
Le texte complet de cet article est disponible en PDF.Key words : MRGPRX2, MRGX2, agonists, chronic spontaneous urticaria, atopic dermatitis, substance P, neuropeptides, eosinophil granule proteins, antimicrobial peptides, pruritus, itch
Abbreviations used : AD, AMP, BAM22, C48/80, CSU, ECP, EDN, EPO, FcεRI, GPCR, hBD-2, hBD-3, HC, MBP-1, MBP-2, MC, MCT, MCTC, MRGPR, NMBA, PAF, PAMP, PTx, SCF, SP, VIP
Plan
| This work was supported by the Russian Academic Excellence Project 5-100. A.E.K. was supported by the German Research Foundation (grants KR3618/3-1 [for 2690] and KR3618/5-1) and the Interdisciplinary Center for Clinical Research at the Friedrich Alexander University of Erlangen-Nürnberg (grants E20 and E27). M.B. was likewise supported by the German Research Foundation (grant BA3769/4-1). This work also benefitted from support of the GA2LEN network of Urticaria Centers of Reference and Excellence (UCARE, www.ga2len-ucare.com). K.W. was supported by a Bavarian Equal Opportunities Sponsorship (Realisierung von Chancengleichheit von Frauen in Forschung und Lehre–Realization Equal Opportunities for Women in Research and Teaching). P.K. was supported by a GA2LEN fellowship. |
|
| Disclosure of potential conflict of interest: P. Kolkhir reports personal fees from Novartis and Roche outside the submitted work. Martin Metz reports personal fees from Aralez, Moxie, Novartis, Roche, Sanofi, and Uriach outside the submitted work. A. E. Kremer reports grants and/or personal fees from AbbVie, Beiersdorf, BMS, CMS, CymaBay, Eisai, Falk, Gilead, GSK, Intercept, Lilly, MSD, and Zambon outside the submitted work. M. Maurer reports grants and/or personal fees from Allakos, Amgen, Aralez, AstraZeneca, BioCryst, Blueprint, Celldex, CSL Behring, FAES, GIInnovation, Genentech, Innate Pharma, Kalvista, Kyowa Kirin, Menarini, Lilly, Leo Pharma, Moxie, MSD, Novartis, Pharming, Pharvaris, Roche, Sanofi, Shire/Takeda, ThirdHarmonicBio, UCB, and Uriach outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 147 - N° 2
P. 456-469 - février 2021 Retour au numéro
Article précédent
- Animal models of psoriasis—highlights and drawbacks
- Michael P. Schön, Veit Manzke, Luise Erpenbeck
- Flow cytometric identification of Tfh13 cells in mouse and human
- Jennifer S. Chen, Jessica D.S. Grassmann, Uthaman Gowthaman, Sam J. Olyha, Tregony Simoneau, M. Cecilia Berin, Stephanie C. Eisenbarth, Adam Williams
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?